Waters news
The WiseView Research desk's stories that name Waters, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The WAT page →
- HeadlineWaters Gears Up to Report Q3 Results: How to Play the Stock?
- HeadlineWaters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
- HeadlineWaters & Labcorp Expand Access to FDA-Approved HPV Screening Tests
- HeadlineWaters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026
- HeadlineWaters Launches AI Link to Advance AI-Enabled LC-MS Workflows
- HeadlineWaters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option
- HeadlineTwo stocks poised to benefit from rotation out of AI
- HeadlineWaters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
- HeadlineHere's Why You Should Retain WAT Stock in Your Portfolio for Now
- HeadlineWaters Corporation Schedules Third Quarter 2026 Earnings Conference Call
- CongressKevin Hern sold $1,001 - $15,000 of WAT
- CongressRo Khanna bought $1,001 - $15,000 of WAT
- CongressThomas Kean sold $1,001 - $15,000 of WAT
- CongressThomas Kean sold $1,001 - $15,000 of WAT
- CongressGilbert Cisneros bought $1,001 - $15,000 of WAT
- CongressRo Khanna bought $1,001 - $15,000 of WAT
- CongressGilbert Cisneros bought $1,001 - $15,000 of WAT
- CongressGilbert Cisneros bought $1,001 - $15,000 of WAT
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.